Evidence map›Paper›PMID 29350055›Full record

ReviewDrug delivery2018

Therapeutic strategies and nano-drug delivery applications in management of ageing Alzheimer's disease.

Govindarajan Karthivashan, Palanivel Ganesan, Shin-Young Park, Joon-Soo Kim, Dong-Kug Choi

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Drug delivery, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 80 papers.

0numbers the graph read from it
0cells of the map it votes in
80citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

80 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Polymeric Nanomaterials for Atherosclerosis Diagnosis and Treatment.Polymer science & technology (Washington, D.C.) · 2025
    Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Article
  19. Review
  20. Review

20 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Govindarajan Karthivashana Department of Biotechnology, College of Biomedical and Health Science , Research Institute of Inflammatory Diseases Konkuk University , Chungju , Republic of Korea.
Palanivel Ganesana Department of Biotechnology, College of Biomedical and Health Science , Research Institute of Inflammatory Diseases Konkuk University , Chungju , Republic of Korea.
Shin-Young Parkb Department of Applied Life Science , Graduate school of Konkuk University , Chungju , Republic of Korea.
Joon-Soo Kimb Department of Applied Life Science , Graduate school of Konkuk University , Chungju , Republic of Korea.
Dong-Kug Choia Department of Biotechnology, College of Biomedical and Health Science , Research Institute of Inflammatory Diseases Konkuk University , Chungju , Republic of Korea.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In recent years, the incidental rate of neurodegenerative disorders has increased proportionately with the aging population. Alzheimer's disease (AD) is one of the most commonly reported neurodegenerative disorders, and it is estimated to increase by roughly 30% among the aged population. In spite of screening numerous drug candidates against various molecular targets of AD, only a few candidates - such as acetylcholinesterase inhibitors are currently utilized as an effective clinical therapy. However, targeted drug delivery of these drugs to the central nervous system (CNS) exhibits several limitations including meager solubility, low bioavailability, and reduced efficiency due to the impediments of the blood-brain barrier (BBB). Current advances in nanotechnology present opportunities to overcome such limitations in delivering active drug candidates. Nanodrug delivery systems are promising in targeting several therapeutic moieties by easing the penetration of drug molecules across the CNS and improving their bioavailability. Recently, a wide range of nano-carriers, such as polymers, emulsions, lipo-carriers, solid lipid carriers, carbon nanotubes, metal based carriers etc., have been adapted to develop successful therapeutics with sustained release and improved efficacy. Here, we discuss few recently updated nano-drug delivery applications that have been adapted in the field of AD therapeutics, and future prospects on potential molecular targets for nano-drug delivery systems.

Indexed as

AgingAlzheimer DiseaseAnimalsCholinesterase InhibitorsDelayed-Action PreparationsDrug Delivery SystemsHumansLipidsNanoparticlesPolymersCholinesterase InhibitorsDelayed-Action PreparationsLipidsPolymersacetylcholineAlzheimer’sCNSmolecular targetsnanodrugsoxidative stress

Identifiers

PMID29350055
PMCPMC6058502

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.